A Phase 2, Randomized Prospective, Double-Masked, Vehicle-Controlled Study to assess the Efficacy and Safety of Nexagon (NEXAGON) Applied Topically in Subjects with Corneal Persistent Epithelial Defects (PED) Resulting from Severe Ocular Chemical and/or
|Effective start/end date||7/15/19 → 7/31/24|
- OCUNEXUS THERAPEUTICS, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.